Deciphera Pharmaceuticals, Inc.
DCPHDelisted Jun 11, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001654151
Deciphera Pharmaceuticals, Inc. was delisted on Jun 11, 2024; its insiders filed their last Form 4 on Jun 11, 2024; 177 institutions reported holding it in 13F filings for Q1 2024, worth $943.7M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Deciphera Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Deciphera Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Sherman Matthew L | EVP & Chief Medical Officer | 0 | Jun 11, 2024 | 0 |
| Allen Patricia L | Director | – | Jun 11, 2024 | 0 |
| Kelly Thomas Patrick | Chief Financial Officer | 0 | Jun 11, 2024 | 0 |
| Squarer Ron | Director | – | Jun 11, 2024 | 0 |
| Kelley Susan L. | Director | – | Jun 11, 2024 | 0 |
| Hoerter Steven L. | President and CEO | 0 | Jun 11, 2024 | 0 |
| Benz Edward J. JR | Director | – | Jun 11, 2024 | 0 |
| Walsh Dennis Leo | Director | 0 | Jun 11, 2024 | 0 |
| Martin John Richard | Director | – | Jun 11, 2024 | 0 |
| Bristol James Arthur | Director | – | Jun 11, 2024 | 0 |
| Martin Daniel C. | Chief Commercial Officer | 0 | Jun 11, 2024 | 0 |
| Dhanak Dashyant | EVP & Chief Scientific Officer | 0 | Jun 11, 2024 | 0 |
| Friedman Franklin Stuart | Director | 0 | Jun 11, 2024 | 0 |
| Pitman Jama | SVP, Chief Development Officer | 0 | Jun 11, 2024 | 0 |
| Brightstar Associates LLC | 10% Owner | 23,107,844 | Apr 24, 2024 | 0 |
| Flynn Daniel Lee | Chief Scientific Officer | 57,158 | Jun 21, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 18, 2022 (view filing) | Feb 16 | 2 days | Martin Daniel C.Chief Commercial Officer | SSale | −1.15K | $9.05 | −$10.4K | −2.3%48.7K after | |
| Feb 18, 2022 (view filing) | Feb 16 | 2 days | Kelly Thomas PatrickChief Financial Officer | SSale | −1.37K | $9.05 | −$12.4K | −2.8%47.8K after | |
| Feb 18, 2022 (view filing) | Feb 16 | 2 days | Pitman JamaSee Remarks | SSale | −1.15K | $9.05 | −$10.4K | −2.9%38.0K after | |
| Oct 6, 2021 (view filing) | Oct 4 | 2 days | Sherman Matthew LEVP & Chief Medical Officer | SSale | −2.66K | $33.17 | −$88.2K | −5.5%46.0K after |